PMID- 16041194
OWN - NLM
STAT- MEDLINE
DCOM- 20060104
LR  - 20220316
IS  - 1075-2765 (Print)
IS  - 1075-2765 (Linking)
VI  - 12
IP  - 4
DP  - 2005 Jul-Aug
TI  - Lidocaine patch treatment in patients with low back pain: results of an 
      open-label, nonrandomized pilot study.
PG  - 311-9
AB  - This prospective, 6-week, multicenter, open-label, nonrandomized pilot study was 
      designed to assess the effectiveness and safety of a lidocaine patch 5% in 
      patients with low back pain (LBP). Patients with moderate to severe LBP, defined 
      as acute/subacute (< 3 months, n = 21), short-term chronic (3-12 months, n = 33), 
      or long-term chronic (> 12 months, n = 77), were recruited from 5 clinics; 
      participants applied < or = 4 patches (560 cm total) once daily to area of 
      maximal LBP as add-on treatment through week 2, with the option to taper 
      concomitant analgesics during weeks 3-6. Scores on Brief Pain Inventory (BPI) 
      were obtained at weeks 2 and 6. Safety analyses included reports of adverse 
      events (AEs) and skin sensitivity to pinprick/light touch. Significant 
      improvements in average daily pain intensity on the BPI were noted at weeks 2 and 
      6 (P < or = 0.001). Significant improvements in pain interference with quality of 
      life (QOL) were noted for all BPI measures of QOL at weeks 2 and 6 for the 
      acute/subacute (P < or = 0.007) and long-term chronic LBP groups (P < 0.0001) and 
      for 5 of 7 BPI measures for the short-term chronic LBP group (P < or = 0.042). 
      Fifty-eight percent of patients reported being "satisfied" or "very satisfied" 
      with treatment. The lidocaine patch was well tolerated. Most common AEs were 
      dizziness and rash (n = 5, 3.8%), and most AEs (80%) were mild to moderate in 
      intensity. Significant improvement in pain intensity and QOL in this cohort of 
      LBP patients was noted during treatment with the lidocaine patch 5%. Controlled 
      clinical trials are warranted.
FAU - Gimbel, Joseph
AU  - Gimbel J
AD  - Arizona Research Center, Phoenix, Arizona 85023, USA. 
      regulatory@azresearchcenter.com
FAU - Linn, Richard
AU  - Linn R
FAU - Hale, Martin
AU  - Hale M
FAU - Nicholson, Bruce
AU  - Nicholson B
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
RN  - 0 (Anesthetics, Local)
RN  - 98PI200987 (Lidocaine)
SB  - IM
MH  - Acute Disease
MH  - Administration, Cutaneous
MH  - Anesthetics, Local/administration & dosage/adverse effects/*therapeutic use
MH  - Chronic Disease
MH  - Female
MH  - Humans
MH  - Lidocaine/administration & dosage/adverse effects/*therapeutic use
MH  - Low Back Pain/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Pain Measurement
MH  - Pilot Projects
MH  - Quality of Life
EDAT- 2005/07/26 09:00
MHDA- 2006/01/05 09:00
CRDT- 2005/07/26 09:00
PHST- 2005/07/26 09:00 [pubmed]
PHST- 2006/01/05 09:00 [medline]
PHST- 2005/07/26 09:00 [entrez]
AID - 00045391-200507000-00006 [pii]
AID - 10.1097/01.mjt.0000164828.57392.ba [doi]
PST - ppublish
SO  - Am J Ther. 2005 Jul-Aug;12(4):311-9. doi: 10.1097/01.mjt.0000164828.57392.ba.